drugset / Trial / NCT01622556
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study to assess the day 180 event free and overall survival after administration of a specified combination of fludarabine, busulfan, Total Body Irradiation (TBI), and thymoglobulin reduced intensity conditioning and 2 unit UCB stem cell transplant in a single institution setting in patients with hematologic malignancies for whom allogeneic transplantation is indicated.
Timeline
- Start
- 2012-01
- Primary completion
- 2014-02
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Busulfan | Small molecule | 0.8 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 35 mg/m2 | Intravenous |
| Background | Influenza Virus Vaccine | Vaccine | — | — |
| Background | Thymoglobulin | Protein / enzyme biologic | 1.5 mg/kg | — |